📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Stifel sets $18 target on Kamada with buy rating

EditorLina Guerrero
Published 07/02/2024, 04:29 PM
KMDA
-

On Tuesday, Stifel initiated coverage on Kamada Ltd . (NASDAQ:KMDA), an Israeli-based global specialty plasma company, with a Buy rating and an $18.00 price target. The firm's analyst highlighted Kamada's diverse portfolio of plasma-based therapeutics and its unique position in markets with high barriers to entry. The company's distribution network spans the US, EU, and MENA regions and is further strengthened by investments in plasma collection centers for both proprietary and third-party use.

Kamada's steady and profitable base business, which has been experiencing double-digit growth, was noted. However, Stifel's coverage is particularly focused on Kamada's development of Inhaled alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency (AATD), a rare and progressive lung disease. The analyst believes this aspect of Kamada's pipeline is currently underappreciated by the market.

The recent acquisition of Inhibrx by Sanofi (NASDAQ:SNY) for $1.7 billion was mentioned as a significant event that has brought increased attention to treatments for AATD. This deal is seen as indicative of the potential value within this therapeutic area.

Stifel's initiation of coverage on Kamada with a positive outlook is based on the company's established specialty plasma business and promising treatment developments. The firm's analyst sees Kamada as a potential major player in the specialty plasma industry, driven by its strategic investments and innovative product pipeline.

In other recent news, Kamada Limited has reported a robust Q1 2024 financial performance. The company's revenues reached $37.7 million, a 23% increase compared to the previous year, and adjusted EBITDA rose by 96% to $7.5 million. This growth was driven by key products KEDRAB and CYTOGAM, and the successful launch of BEVACIZUMAB KAMADA in Israel. As a result, Kamada has raised its full-year revenue and adjusted EBITDA guidance.

Furthermore, Kamada is actively pursuing business development opportunities in plasma-derived and transplantation areas. The company is also preparing for the launch of another biosimilar product by late 2024 or early 2025. In addition, feedback from the FDA on the Inhaled AAT program is expected in the latter part of the year.

While Kamada's growth is dependent on approval in the US or Europe for marketing authorization in Israel, the company has agreements with three biosimilar companies, enhancing its portfolio. These recent developments illustrate Kamada's commitment to steady growth and long-term shareholder value creation.

InvestingPro Insights

As Kamada Ltd. (NASDAQ:KMDA) garners a positive outlook from Stifel, it's valuable to consider the financial health and market performance of the company through InvestingPro metrics. With a market capitalization of $285.67M and a P/E ratio of 20.99, Kamada shows stability in its valuation. The company's revenue growth is particularly impressive, with a 13.33% increase over the last twelve months as of Q1 2024, and an even more robust quarterly growth of 22.88% in Q1 2024. These figures underline the company's expanding market presence and operational efficiency.

InvestingPro Tips further illuminate Kamada's strengths. The company holds more cash than debt, suggesting a solid balance sheet and financial flexibility. Additionally, Kamada's stock is characterized by low price volatility, which may appeal to investors seeking a more stable investment in the biopharmaceutical sector. It is also notable that analysts predict Kamada will be profitable this year, a testament to the company's growth trajectory and the potential underappreciation of its Inhaled AAT program.

For investors intrigued by Kamada's prospects and seeking a deeper analysis, there are additional InvestingPro Tips available, hinting at the company's ability to cover short-term obligations with its liquid assets and its profitability over the last twelve months. Moreover, Kamada's decision not to pay a dividend allows for reinvestment into its promising pipeline, including the development of treatments for AATD. To explore these insights further, consider using the coupon code PRONEWS24 for up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription at InvestingPro. With several more tips available on the platform, investors can gain a comprehensive understanding of Kamada's investment potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.